Attorney Docket: 014811-28.8DV2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ekwuribe, Nnochiri N., et al.

Group Art Unit: 1639

Serial Number: 09/430,735

Examiner: Celsa, Bennett M.

Filed: October 29, 1999

For: METHODS FOR INDUCING ANALGESIA

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 Customer No. 24,239

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND 37 C.F.R. § 1.97

It is respectfully requested that the document listed on the attached Form PTO/SB/08A be considered by the Patent and Trademark Office in the above-referenced application and made of record therein. A full text copy of the relevant document is enclosed. The U.S. Patent and Trademark Office is hereby authorized to charge any deficiency amount necessary for the entry of this Supplemental Information Disclosure Statement to Deposit Account No. 13-4365 of Moore & Van Allen PLLC.

Respectfully submitted,

By:

William A. Barrett
Registration No. 42,296
Attorney for Applicant
Moore & Van Allen, PLLC
2200 West Main Street, Suite 800
Durham, NC 27705

Phone: 919-286-8000

Facsimile: 919-286-8199

August 24, 2004

Date

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service as first class mail on August 24, 2004, in an envelope addressed to Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450

Katrina Holland

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ge required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1695, no erson Complete if Known Substitute for form 1449B/PTO 09/430,735 Application Number SUPPLEMEN Filing Date October 29, 1999 First Named Inventor Ekwuribe, Nnochiri N. INFORMATION DISCLO Art Unit 1639 STATEMENT BY APPLIS Bennett M. Celsa **Examiner Name** (use as many sheets as necessary) 014811-28.8DV2 **Attorney Docket Number** Sheet 1

Examiner Initials* Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (bool magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and country where published. B1 SAKANE, TOSHIYASU, et al., "Carboxyl-directed Pegylation of Brain-derived Neurotrop Factor Markedly Reduces Systemic Clearance with Minimal Loss of Biologic Activity Pharmaceutical Research, Vol. 14, No. 8, pp. 1085-1091, 1997	T ²
Factor Markedly Reduces Systemic Clearance with Minimal Loss of Biologic Activi	or
	nic y,"
Examiner Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.